NEJM This Week — March 5, 2026

Why It Matters

These findings could reshape treatment algorithms for diabetic kidney disease, acute coronary care, and rare‑disease therapeutics, while financial insights signal shifting capital structures in healthcare.

Key Takeaways

• Finerenone reduces CKD progression in type‑1 diabetes
• Early non‑culprit PCI improves STEMI outcomes
• New gene‑therapy shows promise for Dravet syndrome
• Neoadjuvant regimen extends survival in cholangiocarcinoma
• Private‑equity trends reshape healthcare financing

Pulse Analysis

The phase‑3 finerenone trial marks a significant advance for patients with type‑1 diabetes complicated by chronic kidney disease. By targeting mineralocorticoid receptors, the drug demonstrated a measurable slowdown in eGFR decline and reduced albuminuria, outcomes that could translate into fewer dialysis referrals and lower cardiovascular risk. Clinicians are now weighing finerenone alongside SGLT2 inhibitors, potentially redefining standard-of‑care protocols for renal protection in a population historically underserved by existing therapies.

Concurrently, updated consensus on non‑culprit‑lesion percutaneous coronary intervention (PCI) after ST‑segment elevation myocardial infarction (STEMI) recommends earlier revascularization, citing data that earlier intervention reduces repeat ischemic events without increasing bleeding risk. The episode also spotlighted an investigational antisense oligonucleotide therapy for Dravet syndrome, which showed seizure frequency reductions in early‑phase trials, offering hope for a disorder with limited options. In oncology, a neoadjuvant combination of gemcitabine, cisplatin, and targeted agents extended resectability rates for high‑risk intrahepatic cholangiocarcinoma, suggesting a shift toward pre‑operative systemic control.

Beyond clinical breakthroughs, the discussion touched on radiotherapy’s collateral effects on normal tissue, underscoring the need for precision techniques to mitigate long‑term toxicity. A perplexing case of progressive neurologic decline after a suspected foodborne illness highlighted diagnostic challenges in neuro‑infectious diseases. Finally, perspectives on private‑equity influx, the AHEAD financing model, and the rise of medical credit cards illustrate how capital and payment innovations are reshaping provider economics and patient access, signaling a broader transformation in the healthcare ecosystem.

Original Description

This week, we explore a phase 3 trial of finerenone in type 1 diabetes and chronic kidney disease and guidance on timing of nonculprit-lesion PCI after STEMI. We cover an investigational therapy for Dravet syndrome and neoadjuvant treatment for high-risk intrahepatic cholangiocarcinoma. We review the effects of radiotherapy on normal tissue, a puzzling case of progressive neurologic decline after suspected foodborne illness, and Perspectives on private equity, the AHEAD model, and medical credit cards.